Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 4
2020 2
2021 2
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
Papeix C, Donze C, Lebrun-Frénay C; French Group for Recommendations in Multiple Sclerosis (France4MS), the Société Francophone de la Sclérose En Plaques (SFSEP); Co-Chairs; Group of evaluators Coordinators; Readers; Cotator; Expert readers (voters). Papeix C, et al. Rev Neurol (Paris). 2021 Oct;177(8):980-994. doi: 10.1016/j.neurol.2021.04.011. Epub 2021 Jul 21. Rev Neurol (Paris). 2021. PMID: 34303537
Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study.
Levraut M, Laurent-Chabalier S, Ayrignac X, Bigaut K, Rival M, Squalli S, Zéphir H, Alberto T, Pekar JD, Ciron J, Biotti D, Puissant-Lubrano B, Camdessanché JP, Tholance Y, Casez O, Toussaint B, Marion J, Moreau T, Lakomy D, Thomasset A, Maillart E, Sterlin D, Maurousset A, Rocher A, Laplaud DA, Bigot-Corbel E, Bertho PO, Pelletier J, Boucraut J, Labauge P, Vincent T, De Sèze J, Jahn I, Seitz-Polski B, Thouvenot E, Lebrun-Frenay C; Société Francophone de la Sclérose En Plaques (SFSEP). Levraut M, et al. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 14;10(1):e200049. doi: 10.1212/NXI.0000000000200049. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36376096 Free PMC article.
Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis.
Androdias G, Noroy L, Psimaras D, Birzu C, Pelletier J, Beigneux Y, Branger P, Ciron J, Dananchet Y, Depaz R, Froment Tilikete C, Gignoux L, Grosset-Janin C, Joubert B, Kerschen P, Kwiatkowski A, Lebrun-Frenay C, Maillart E, Maureille A, Nicolas P, Roux T, Marignier R, Vukusic S; as the ICI-SEP group, under the aegis of the Société Francophone de la Sclérose en Plaques (SFSEP). Androdias G, et al. Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200202. doi: 10.1212/NXI.0000000000200202. Epub 2024 Feb 12. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38346268 Free PMC article.
First clinical inflammatory demyelinating events of the central nervous system in a population aged over 70 years: A multicentre study.
Lavandier N, Bonnan M, Carra-Dallière C, Charif M, Labauge P, Camdessanche JP, Edan G, Naudin A, Brassat D, Ciron J, Clavelou P, Dulau C, Moroso A, Brochet B, Ouallet JC; on behalf Société Francophone de la Sclérose en Plaques (SFSEP). Lavandier N, et al. Mult Scler Relat Disord. 2019 Feb;28:309-312. doi: 10.1016/j.msard.2018.12.016. Epub 2018 Dec 14. Mult Scler Relat Disord. 2019. PMID: 30665072
Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial.
Defer G, Fedrizzi S, Chevanne D, Montastruc F, Briant AR, Parienti JJ, Peyro-Saint-Paul L; French VigipSEP Study Group; Société Francophone de la Sclérose en Plaques (SFSEP). Defer G, et al. Drug Saf. 2021 Feb;44(2):223-233. doi: 10.1007/s40264-020-01009-z. Epub 2020 Oct 13. Drug Saf. 2021. PMID: 33048319 Clinical Trial.
Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society.
Donzé C, Papeix C, Lebrun-Frenay C; French Group for Recommendations in Multiple Sclerosis (France4MS); Société francophone de la sclérose en plaques (SFSEP); SPILF; Co-chairs; Supervision of the readers; Readers; Rating group; Reading group. Donzé C, et al. Rev Neurol (Paris). 2020 Dec;176(10):804-822. doi: 10.1016/j.neurol.2020.02.011. Epub 2020 Sep 5. Rev Neurol (Paris). 2020. PMID: 32900473
The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
Makhani N, Lebrun-Frenay C, Siva A, Shabanova V, Wassmer E, Santoro JD, Narula S, Brenton JN, Mar S, Durand-Dubief F, Zephir H, Mathey G, Rojas JI, de Seze J, Tenembaum S, Stone RT, Casez O, Carra-Dallière C, Neuteboom RF, Ahsan N, Arroyo HA, Cabre P, Gombolay G, Inglese M, Louapre C, Margoni M, Palavra F, Pohl D, Reich DS, Ruet A, Thouvenot E, Timby N, Tintore M, Uygunoglu U, Vargas W, Venkateswaran S, Verhelst H, Wickstrom R, Azevedo CJ, Kantarci O, Shapiro ED, Okuda DT, Pelletier D; Observatoire Francophone de la Sclérose en Plaques (OFSEP), Société Francophone de la Sclérose en Plaques (SFSEP), Radiologically Isolated Syndrome Consortium (RISC), and the Pediatric Radiologically Isolated Syndrome Consortium (PARIS). Makhani N, et al. J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12289-1. Online ahead of print. J Neurol. 2024. PMID: 38564056
Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M; Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network. Fissolo N, et al. Ann Neurol. 2017 Aug;82(2):186-195. doi: 10.1002/ana.24987. Epub 2017 Jul 22. Ann Neurol. 2017. PMID: 28681388 Clinical Trial.
11 results